Oma Fertility vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Oma Fertility operates affordable mini IVF clinics using a lower-stimulation protocol that reduces medication costs and side effects, making IVF accessible to more patients.
About
Oma Fertility is a fertility clinic company founded in 2019 that operates a network of fertility clinics using minimal stimulation IVF (mini IVF) as a primary treatment approach, offering IVF at significantly lower cost than conventional high-stimulation protocols. Mini IVF uses fewer and lower doses of fertility medications, reducing medication costs from $3,000-5,000 to a fraction of that amount while also decreasing the risk of ovarian hyperstimulation syndrome. Oma pairs this lower-cost clinical model with efficient clinic operations, transparent pricing, and subscription plans that make ongoing IVF cycles economically sustainable for patients who might otherwise not afford conventional IVF. The company has raised $40M and operates multiple clinic locations primarily in the Midwest and Southeast United States, targeting the large population of fertility patients who are priced out of conventional IVF at $20,000+ per cycle. Oma Fertility has positioned itself in the value segment of the fertility clinic market, complementing premium networks like Kindbody by serving cost-conscious patients who prioritize affordability and accessibility over premium clinic amenities.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.